Treatment of cancer cells with c-Src inhibitor, PP2, or Twist siRNA significantly blocks the production of HA/CD44-mediated miR-10 expression and downstream RhoGTPase (RhoC)-ROK effector functions (89). Here, SRC is linked to cancer.